West Pharma Executive Says CGM Program Decline Contributed to Q3 Revenue Drop
A West Pharma executive said a decline in the CGM program contributed to a Q3 revenue drop at West Vantage.
Related stories
Bioextrax Raises About SEK 6 Million in Private Placement
Bioextrax says its private placement was fully subscribed.
M impact | EQUITY | Oct 29, 2026, 02:50 PM UTC
Adidas CEO Keeps Q4 Revenue Guidance at 9% to 10%
The CEO said Adidas kept its Q4 revenue guidance at 9% to 10% and that there might be upside.
M impact | EQUITY | Oct 29, 2026, 02:50 PM UTC
General Mining reports Q3 profit of 13,869 dinars
M impact | EQUITY | Oct 29, 2026, 02:49 PM UTC
Grupo Aeroportuario del Pacifico Announces Dividend of R$ 0.3601412040 per Unit
M impact | EQUITY | Oct 29, 2026, 02:49 PM UTC
PVH Announces R$ 0.067727273 per BDR Dividend
PVH announced a fourth-quarter 2026 dividend of R$ 0.067727273 per BDR.
M impact | EQUITY | Oct 29, 2026, 02:49 PM UTC
Proto Labs Reports Quarterly Results Through September 30
M impact | EQUITY | Oct 29, 2026, 02:49 PM UTC